Ibrahim Rafwana, Aranjani Jesil Mathew, Kalikot Valappil Vipin, Nair Gouri
Department of Pharmaceutical Biotechnology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India.
Department of Pharmaceutics, College of Pharmaceutical Sciences, Government Medical College, Kannur, India.
Future Sci OA. 2025 Dec;11(1):2468114. doi: 10.1080/20565623.2025.2468114. Epub 2025 Feb 20.
Antimicrobial resistance renders conventional therapy, demanding the need for alternative therapeutic techniques. A potential strategy for treating infections caused by multi-drug-resistant bacteria is using bacteriophages, viruses that only multiply and infect specific bacteria. This review aims to evaluate the findings of clinical studies on phage therapy for bacterial illnesses.
A comprehensive search method was utilized to identify 11 appropriate trials, which were then assessed for safety, efficacy, and treatment outcomes. The Joann-Briggs-Institute checklist and PRISMA criteria were used to evaluate these studies thoroughly. The results were summarized by extracting and analyzing data on trial design, treatment outcomes, safety profiles, and therapeutic effectiveness.
Phage treatment had a strong safety profile, with few side effects recorded across many routes, including oral, intravenous, and topical. Clinical studies demonstrated its effectiveness in lowering bacterial loads, resolving infections, and destroying biofilms. However, diversity in trial designs hampered the generalizability of the findings.
This study emphasizes the promise of phage therapy as a safe and efficient treatment for bacterial-illnesses. Despite its potential, there are still significant gaps in clinical application, long-term efficacy assessment, and trial standardization. Addressing these issues is critical to developing phage therapy as an effective alternative treatment for multidrug-resistant-illnesses.
抗生素耐药性使得传统治疗方法受到挑战，因此需要替代性治疗技术。治疗多重耐药菌引起的感染的一种潜在策略是使用噬菌体，即仅在特定细菌中繁殖并感染它们的病毒。本综述旨在评估噬菌体疗法治疗细菌性疾病的临床研究结果。
采用全面的检索方法确定了11项合适的试验，然后对这些试验的安全性、有效性和治疗结果进行评估。使用乔安娜·布里格斯研究所核对清单和PRISMA标准对这些研究进行全面评估。通过提取和分析关于试验设计、治疗结果、安全性概况和治疗效果的数据来总结结果。
噬菌体治疗具有良好的安全性，在包括口服、静脉注射和局部应用在内的多种给药途径中记录到的副作用很少。临床研究证明其在降低细菌载量、解决感染和破坏生物膜方面的有效性。然而，试验设计的多样性阻碍了研究结果的普遍性。
本研究强调了噬菌体疗法作为治疗细菌性疾病的一种安全有效方法的前景。尽管其具有潜力，但在临床应用、长期疗效评估和试验标准化方面仍存在重大差距。解决这些问题对于将噬菌体疗法发展成为治疗多重耐药性疾病的有效替代疗法至关重要。
